Skip to main content
SpringerLink
Log in

Biosimilars in the Treatment of Inflammatory Bowel Disease

  • Chapter
  • First Online:
Crohn's Disease and Ulcerative Colitis

  • 3509 Accesses

Abstract

Inflammatory bowel disease (IBD) is often treated with biologic agents, such as infliximab, a monoclonal antibody against tumor necrosis factor (TNF)-α. Biosimilars are biologic agents developed to have similar biological properties in terms of safety and efficacy as the reference or innovator biologic. The development of biosimilars requires extensive preclinical testing, but entry of biosimilars into the clinical market does not require as extensive clinical testing as for innovator biologics. Since biologics such as infliximab are clinically indicated for rheumatologic conditions as well as for IBD, and biosimilar infliximab has been shown to be efficacious in the treatment of rheumatologic and other inflammatory conditions, there are concerns regarding the appropriateness of clinical extrapolation of the indication for biosimilar infliximab to the treatment of IBD. This chapter summarizes the issues surrounding the use of biosimilars in the treatment of IBD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet. 2002;359(9317):1541–9.

    Article  CAS  PubMed  Google Scholar 

  2. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulising Crohn’s disease. N Engl J Med. 2004;350(9):876–85.

    Article  CAS  PubMed  Google Scholar 

  3. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76.

    Article  CAS  PubMed  Google Scholar 

  4. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33.

    Article  CAS  PubMed  Google Scholar 

  5. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Pannaccionne R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.

    Article  CAS  PubMed  Google Scholar 

  6. Reinisch W, Sandborn WH, Hommes DW, D’Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial. Gut. 2011;60(6):780–7.

    Article  CAS  PubMed  Google Scholar 

  7. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–265.e13.

    Google Scholar 

  8. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95.

    Article  CAS  PubMed  Google Scholar 

  9. Sandborn WJ, Feagan BG, Marano C, Shang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109.

    Article  CAS  PubMed  Google Scholar 

  10. World Health Organization (WHO). Guidelines on evaluation of similar biotherapeutic products (SBPs). Available from: http://www.who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf?ua=1. Cited 26 June 2015.

  11. European Medicines Agency (EMA). Guideline on similar biologic medicinal products. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Cited 26 June 2015.

  12. Epstein MS, Ehrenpreis ED, Kulkarni PM. FDA-Related Matters Committee of the American College of Gastroenterology. Biosimilars: the need, the challenge, the future: the FDA perspective. Am J Gastroenterol. 2014;109(12):1856–9.

    Article  PubMed  Google Scholar 

  13. Health Canada. Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs). Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2010-eng.pdf. Cited 26 June 2015.

  14. Ramanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs. 2014;28(4):363–72.

    Article  PubMed  Google Scholar 

  15. Bui LA, Hurst S, Finch GL, Ingram B, Jacobs IA, Kirchhoff CF, et al. Key considerations in the preclinical development of biosimilars. Drug Discov Today. 2015;20 Suppl 1:3–15.

    Article  CAS  PubMed  Google Scholar 

  16. Van Aerts L, de Smet K, Reichmann G, van der Lann JW, Schneider CK. Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union. MAbs. 2014;6(5):1155–62.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191–6.

    Article  CAS  PubMed  Google Scholar 

  18. McCamish M, Pakulski J, Sattler C, Woolett G. Toward interchangeable biologics. Clin Pharmacol Ther. 2015;97(3):215–7.

    Article  CAS  PubMed  Google Scholar 

  19. Federal Drug Agency (FDA). Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product: guidance for industry. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformatin/Guidances/UCM291134.pdf. Cited 26 June 2015.

  20. Federal Drug Agency (FDA). Scientific considerations in demonstrating biosimilarity to a reference product. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Cited 26 June 2015.

  21. McKeage K. A review of CT-P13: an infliximab biosimilar. BioDrugs. 2014;28:313–21.

    Article  CAS  PubMed  Google Scholar 

  22. Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, et al. Physicochemical characterization of Remsima®. MAbs. 2014;6(5):1163–77.

    Article  PubMed  PubMed Central  Google Scholar 

  23. European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP). Assessment report: Remsima (infliximab); 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf. Cited 18 July 2015.

  24. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomized, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomized, double-blind, multicenter, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–12. doi:10.1136/annrheumdis-2012-203091.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Baji P, Pentek M, Czirjak L, Szekanecz Z, Nagy G, Gulacsi L, et al. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eu J Heatlh Econ. 2014;15 Suppl 1:S53–64.

    Article  Google Scholar 

  27. Baji P, Pentek M, Szanto S, Geher P, Gulacsi L, Balogh O, et al. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: a systematic literature review and meta-analysis. Eur J Health Econ. 2014;15 Suppl 1:S45–52.

    Article  PubMed  Google Scholar 

  28. Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, et al. Review: the challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42:177–83.

    Article  CAS  PubMed  Google Scholar 

  29. Hlavaty T, Letkovsky J. Biosimilars in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2014;26:581–7.

    CAS  PubMed  Google Scholar 

  30. Feldman SR. Inflammatory diseases: integrating biosimilars into clinical practice. Semin Arhtritis Rheum. 2015;44:S16–21.

    Article  Google Scholar 

  31. Kay J, Wyand M, Chandrashekara S, Olakkengil DJ, Bhojani K, Bhatia G, et al. BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis on stable methotrexate disease: 54-week results of a randomized, double-blind, active comparator study. In: Bucala RJ, editor. 2014 ACR/ARHP Annual Meeting, Boston, MA. Arthritis Rheumatol. 2014;66(S10):S1–1402.

    Article  Google Scholar 

  32. Kang T, Moon H, Lee S, Lim YJ, Kang HW. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60(4):951–6.

    Article  CAS  PubMed  Google Scholar 

  33. Jung YS, Park DI, Kim YH, Lee JH, Seo PJ, Cheon JH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30(12):1705–12.

    Google Scholar 

  34. Farkas K, Rutka M, Balint A, Nagy F, Bor R, Milassin A, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis—experiences from a single center. Expert Opin Biol Ther. 2015;2:1–6.

    Google Scholar 

  35. Gecse KB, Lovasz BD, Farkas K, Banai J, Bene L, Gasztonyi B, et al. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort. J Crohns Colitis 2016;10(2):133–140.

    Google Scholar 

  36. Jahnsen J, Detlie TE, Vatn S, and Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Rev Gastroenterol Hepatol 2015;9(S1):S45–S52.

    Google Scholar 

  37. Murphy C, Sugrue K, Mohamad G, McCarthy J, Buckley M. P505: biosimilar but not the same. In: Egan LJ, editor. 10th congress of ECCO, February 18–21, 2015, Barcelona, Spain. J Crohns Colitis. 2015;9 Suppl 1:S331.

    Google Scholar 

  38. Fiorino G, Danese S. The biosimilar road in inflammatory bowel disease: the right way? Best Pract Res Clin Gastroenterol. 2014;28:465–71.

    Article  PubMed  Google Scholar 

  39. Sieczkowksa J, Jarzebicka D, Banaszkiewicz A, Plocek A, Gawronska A, Toporowska-Kowalska E, et al. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations. J Crohns Colitis 2016;10(2):127–32.

    Google Scholar 

  40. A randomized, double-blind, parallel-group study to evaluate the safety and efficacy of switching from innovator infliximab to biosimilar infliximab compared with continued treatment with innovator infliximab in patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn’s disease and chronic plaque psoriasis—The NOR-SWITCH Study. Available from: https://clinicaltrials.gov/ct2/show/NCT02148640. Cited 26 June 2015.

  41. Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut 2015;0:1-7. doi:10.1136gutjnl-2015-309290 (online first).

    Google Scholar 

  42. Brodszky V, Baji P, Balogh O, Pentek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Easter European countries. Eur J Health Econ. 2014;15 Suppl 1:S65–71.

    Article  PubMed  Google Scholar 

  43. Jha A, Upton A, Dunlop WC, Akehurst R. The Budget Impact of BIosimlar Infliximab (Remsima(R) for the Treatment of Autoimmune Diseases in Five European Countries. Adv Ther 2015;32(8):742–56.

    Google Scholar 

  44. Blackstone EA, Fuhr JP. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469–78.

    PubMed  PubMed Central  Google Scholar 

  45. Baji P, Gulacsi L, Lovascz BD, Golovics PA, Brodsky V, Pentek M, et al. Treatment preferences of originator versus biosimilar drugs in Crohn’s disease; discrete choice experiment among gastroenterologists. Scan J Gastroenterol. 2015;10:1–6.

    Google Scholar 

  46. Azevedo V, Meirelles E, Kochen J, Mederios A Miszputen S, Teixeira F, et al. Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease – Focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases. Autoimmun Rev. 2015 May 1. pii: S1568-9972(15)00106-8. doi:10.1016/j.autrev.2015.04.014. [Epub ahead of print].

  47. British Society of Gastroenterology. IBD Section Statement on Biosimilar Drugs. Available from: http://www.bsg.org.uk/clinical-guidance/ibd/ibd-section-statement-on-biosimilar-drugs.html. Cited 26 June 2015.

  48. Devlin SM, Bressler B, Bernstein CN, Fedorak RN, Bitton A, Singh H, et al. Review: overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol. 2013;27(10):567–71.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Annese V, Vecchi M. On behalf of the Italian Group for the Study of IBD (IG-IBD). Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. Dig Liver Dis. 2014;46:963–8.

    Article  PubMed  Google Scholar 

  50. Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;87:586–9.

    Article  Google Scholar 

  51. Arguelles-Arias F, Barreiro-de-Acosta M, Carballo F, Hinojosa J, Tejerina T. Joint position statement by “Sociedad Espanola de Patologia Digestiva” (Spanish Society of Gastroenterology) and “Sociedad Espanola de Farmacologia” (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease. Rev Esp Enferm Dig (Madrid). 2013;105(1):37–43.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Zeidler Ledcor Centre, University of Alberta, 8540—112 Street, Edmonton, AB, T6G 2X8, Canada

    Vivian W. Huang M.Sc., M.D., F.R.C.P.C. & Richard N. Fedorak M.D., F.R.C.P.C., F.R.S.C.

Authors
  1. Vivian W. Huang M.Sc., M.D., F.R.C.P.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard N. Fedorak M.D., F.R.C.P.C., F.R.S.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard N. Fedorak M.D., F.R.C.P.C., F.R.S.C. .

Editor information

Editors and Affiliations

  1. Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Charité Medical School—Humboldt-University of Berlin, Berlin, Germany

    Daniel C. Baumgart

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Huang, V.W., Fedorak, R.N. (2017). Biosimilars in the Treatment of Inflammatory Bowel Disease. In: Baumgart, D. (eds) Crohn's Disease and Ulcerative Colitis. Springer, Cham. https://doi.org/10.1007/978-3-319-33703-6_47

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33703-6_47

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33701-2

  • Online ISBN: 978-3-319-33703-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation